MLchartDataset catalogue

Tarenflurbil

Term · Oncology and biomedicine · MLC-T-ONC-016984

An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. Tarenflurbil does not inhibit the enzyme cyclo-oxygenase.

Table 1. Record
IdentifierMLC-T-ONC-016984
FieldOncology and biomedicine
SynonymsR-flurbiprofen
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016984",
  "term": "Tarenflurbil",
  "field": "Oncology and biomedicine",
  "definition": "An orally active synthetic enantiomer of flurbiprofen. Tarenflurbil activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. Tarenflurbil does not inhibit the enzyme cyclo-oxygenase.",
  "synonyms": [
    "R-flurbiprofen"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tarenflurbil/"
}

Record 15,994 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.